Bank Of Montreal

Direxion Daily Small Cap Bull 3X ETF

SPDR S&P Retail ETF

ProShares UltraPro Dow30

ProShares UltraShort Bloomberg Natrl Gas

Guggenheim Solar ETF

Direxion Technology Bear 3X Shares

Materials Select Sector SPDR

ProShares Trust ProShares Short Bitcoin Strategy ETF

ProShares Bitcoin Strategy ETF

Direxion Daily Small Cap Bear 3X ETF

ProShares Ultra Bloomberg Natural Gas

Direxion Daily Technology Bull 3X ETF

ARK Innovation ETF

Direxion Dly S&P Oil&Gs Ex&Prd Br 3X ETF

Magal Security Systems Ltd.

Direxion Financial Bear 3X Shar

Direxion Daily Semicondct Bull 3X ETF

JELD-WEN Holding Inc. Common Stock

Las Vegas Sands Corp. Common Stock

Century Communities Inc. Common Stock

Kontoor Brands Inc. Common Stock

Bath & Body Works Inc.

RLJ Lodging Trust Common Shares of Beneficial Interest $0.01 par value

Leggett & Platt Incorporated Common Stock

Snap Inc. Class A Common Stock

Cleveland-Cliffs Inc. Common Stock

Civitas Resources Inc. Common Stock

Archer Aviation Inc. Class A Common Stock

AMC Entertainment Holdings Inc. Class A Common Stock

Oklo Inc.

QuantumScape Corporation Class A Common Stock

Sea Limited American Depositary Shares each representing one Class A Ordinary Share

Cameco Corporation Common Stock

Twilio Inc. Class A Common Stock

Spotify Technology S.A. Ordinary Shares

Cloudflare Inc. Class A Common Stock

Molina Healthcare Inc Common Stock

Click here to get full coverage on Wall Street Analysts See an 89.66% Upside in Metsera Inc. (MTSR): Can the Stock Really Move This High? - Yahoo Finance

Wall Street Analysts See an 89.66% Upside in Metsera Inc. (MTSR): Can the Stock Really Move This High?  Yahoo Finance

Wall Street Analysts See an 89.66% Upside in Metsera Inc. (MTSR): Can the Stock Really Move This High? - Yahoo Finance

Click here to get full coverage on Promising Results Of Amylin Analogs In Obesity: Metsera Case Review (NASDAQ:MTSR) - Seeking Alpha

Promising Results Of Amylin Analogs In Obesity: Metsera Case Review (NASDAQ:MTSR)  Seeking Alpha

Promising Results Of Amylin Analogs In Obesity: Metsera Case Review (NASDAQ:MTSR) - Seeking Alpha

Click here to get full coverage on MTSR Stock Price and Chart — NASDAQ:MTSR - TradingView

MTSR Stock Price and Chart — NASDAQ:MTSR  TradingView

MTSR Stock Price and Chart — NASDAQ:MTSR - TradingView

Click here to get full coverage on Weight Loss Drug Shows 8.4% Reduction in Phase 1 Trial, Monthly Dosing Success | MTSR Stock News - Stock Titan

Weight Loss Drug Shows 8.4% Reduction in Phase 1 Trial, Monthly Dosing Success | MTSR Stock News  Stock Titan

Weight Loss Drug Shows 8.4% Reduction in Phase 1 Trial, Monthly Dosing Success | MTSR Stock News - Stock Titan

Click here to get full coverage on MTSR IPO News - Obesity biotech Metsera offers fewer shares, prices IPO above the range at $18 - renaissancecapital.com

MTSR IPO News - Obesity biotech Metsera offers fewer shares, prices IPO above the range at $18  renaissancecapital.com

MTSR IPO News - Obesity biotech Metsera offers fewer shares, prices IPO above the range at $18 - renaissancecapital.com

Click here to get full coverage on Obesity Newcomer Metsera Enters The Ring With A Punch — And A Big Stock Jump - Investor's Business Daily

Obesity Newcomer Metsera Enters The Ring With A Punch — And A Big Stock Jump  Investor's Business Daily

Obesity Newcomer Metsera Enters The Ring With A Punch — And A Big Stock Jump - Investor's Business Daily

Click here to get full coverage on Metsera’s Amylin Drug Looks Good in Phase 1, Shows Potential to be a Once-Monthly Obesity Med - MedCity News

Metsera’s Amylin Drug Looks Good in Phase 1, Shows Potential to be a Once-Monthly Obesity Med  MedCity News

Metsera’s Amylin Drug Looks Good in Phase 1, Shows Potential to be a Once-Monthly Obesity Med - MedCity News

Click here to get full coverage on Metsera extends gains after early-stage trial data for obesity therapy - MSN

Metsera extends gains after early-stage trial data for obesity therapy  MSN

Metsera extends gains after early-stage trial data for obesity therapy - MSN

Click here to get full coverage on Metsera Moves Fast in Crowded Obesity Market With IPO Plans - BioSpace

Metsera Moves Fast in Crowded Obesity Market With IPO Plans  BioSpace

Metsera Moves Fast in Crowded Obesity Market With IPO Plans - BioSpace

Click here to get full coverage on Metsera, Inc. Reports Positive Phase 1 Trial Results - TipRanks

Metsera, Inc. Reports Positive Phase 1 Trial Results  TipRanks

Metsera, Inc. Reports Positive Phase 1 Trial Results - TipRanks

Click here to get full coverage on Metsera, Inc.(NasdaqGS: MTSR) added to S&P Biotechnology Select Industry Index - MarketScreener

Metsera, Inc.(NasdaqGS: MTSR) added to S&P Biotechnology Select Industry Index  MarketScreener

Metsera, Inc.(NasdaqGS: MTSR) added to S&P Biotechnology Select Industry Index - MarketScreener

Click here to get full coverage on Metsera Hits New High As Obesity Pipeline Gains Weight - RTTNews

Metsera Hits New High As Obesity Pipeline Gains Weight  RTTNews

Metsera Hits New High As Obesity Pipeline Gains Weight - RTTNews

Click here to get full coverage on Cantor Fitzgerald reiterates Metsera stock rating on strong MET-233i results - Investing.com

Cantor Fitzgerald reiterates Metsera stock rating on strong MET-233i results  Investing.com

Cantor Fitzgerald reiterates Metsera stock rating on strong MET-233i results - Investing.com

Click here to get full coverage on Metsera Unveils First-in-Class Once-Monthly Amylin Candidate MET-233i’s Positive Phase 1 Results - Yahoo Finance

Metsera Unveils First-in-Class Once-Monthly Amylin Candidate MET-233i’s Positive Phase 1 Results  Yahoo Finance

Metsera Unveils First-in-Class Once-Monthly Amylin Candidate MET-233i’s Positive Phase 1 Results - Yahoo Finance

Click here to get full coverage on MTSR IPO News - Obesity biotech Metsera sets terms for $275 million IPO - renaissancecapital.com

MTSR IPO News - Obesity biotech Metsera sets terms for $275 million IPO  renaissancecapital.com

MTSR IPO News - Obesity biotech Metsera sets terms for $275 million IPO - renaissancecapital.com

Click here to get full coverage on Metsera Clears Key Benchmark, Hitting 80-Plus RS Rating - Investor's Business Daily

Metsera Clears Key Benchmark, Hitting 80-Plus RS Rating  Investor's Business Daily

Metsera Clears Key Benchmark, Hitting 80-Plus RS Rating - Investor's Business Daily

Click here to get full coverage on Is Metsera, Inc. (MTSR) Among Stocks With At Least $20 Million In Insider Spending Recently? - Yahoo Finance

Is Metsera, Inc. (MTSR) Among Stocks With At Least $20 Million In Insider Spending Recently?  Yahoo Finance

Is Metsera, Inc. (MTSR) Among Stocks With At Least $20 Million In Insider Spending Recently? - Yahoo Finance

Click here to get full coverage on Metsera, Inc.'s S&P Biotech Index Inclusion: A Catalyst-Driven Opportunity for Growth Investors - AInvest

Metsera, Inc.'s S&P Biotech Index Inclusion: A Catalyst-Driven Opportunity for Growth Investors  AInvest

Metsera, Inc.'s S&P Biotech Index Inclusion: A Catalyst-Driven Opportunity for Growth Investors - AInvest

Click here to get full coverage on 13 Biotech Stocks with Huge Upside Potential - Insider Monkey

13 Biotech Stocks with Huge Upside Potential  Insider Monkey

13 Biotech Stocks with Huge Upside Potential - Insider Monkey

Click here to get full coverage on Metsera shares soar on positive amylin candidate trial results - Investing.com

Metsera shares soar on positive amylin candidate trial results  Investing.com

Metsera shares soar on positive amylin candidate trial results - Investing.com

Click here to get full coverage on Decoding Metsera Inc (MTSR): A Strategic SWOT Insight - GuruFocus

Decoding Metsera Inc (MTSR): A Strategic SWOT Insight  GuruFocus

Decoding Metsera Inc (MTSR): A Strategic SWOT Insight - GuruFocus

Click here to get full coverage on Metsera Readies $275 Million IPO For Obesity Treatments (Pending:MTSR) - Seeking Alpha

Metsera Readies $275 Million IPO For Obesity Treatments (Pending:MTSR)  Seeking Alpha

Metsera Readies $275 Million IPO For Obesity Treatments (Pending:MTSR) - Seeking Alpha

Click here to get full coverage on Metsera: MTSR IPO, Health Care - Phase 2 biotech developing nutrient stimulated hormone analog peptides for obesity. - renaissancecapital.com

Metsera: MTSR IPO, Health Care - Phase 2 biotech developing nutrient stimulated hormone analog peptides for obesity.  renaissancecapital.com

Metsera: MTSR IPO, Health Care - Phase 2 biotech developing nutrient stimulated hormone analog peptides for obesity. - renaissancecapital.com

Click here to get full coverage on MTSR IPO News - Obesity biotech Metsera files for a $100 million IPO - renaissancecapital.com

MTSR IPO News - Obesity biotech Metsera files for a $100 million IPO  renaissancecapital.com

MTSR IPO News - Obesity biotech Metsera files for a $100 million IPO - renaissancecapital.com

Click here to get full coverage on Metsera: A Must-Add To Your Watchlist Thanks To GLP-1 Obesity Promise (NASDAQ:MTSR) - Seeking Alpha

Metsera: A Must-Add To Your Watchlist Thanks To GLP-1 Obesity Promise (NASDAQ:MTSR)  Seeking Alpha

Metsera: A Must-Add To Your Watchlist Thanks To GLP-1 Obesity Promise (NASDAQ:MTSR) - Seeking Alpha

Click here to get full coverage on Metsera Reports First Quarter 2025 Financial Results and Continued Portfolio Progress - GlobeNewswire

Metsera Reports First Quarter 2025 Financial Results and Continued Portfolio Progress  GlobeNewswire

Metsera Reports First Quarter 2025 Financial Results and Continued Portfolio Progress - GlobeNewswire

Click here to get full coverage on Metsera: Capturing Of Obesity Market With Long-Acting GLP-1 Differentiation - Seeking Alpha

Metsera: Capturing Of Obesity Market With Long-Acting GLP-1 Differentiation  Seeking Alpha

Metsera: Capturing Of Obesity Market With Long-Acting GLP-1 Differentiation - Seeking Alpha

Click here to get full coverage on Metsera Stock Rises As Company Advances Obesity Pipeline With Encouraging Weight Loss Data - Benzinga

Metsera Stock Rises As Company Advances Obesity Pipeline With Encouraging Weight Loss Data  Benzinga

Metsera Stock Rises As Company Advances Obesity Pipeline With Encouraging Weight Loss Data - Benzinga

Click here to get full coverage on Metsera Shows Rising Price Performance With Jump To 92 RS Rating - Investor's Business Daily

Metsera Shows Rising Price Performance With Jump To 92 RS Rating  Investor's Business Daily

Metsera Shows Rising Price Performance With Jump To 92 RS Rating - Investor's Business Daily

Click here to get full coverage on Metsera Reports Fourth Quarter and Full Year 2024 Financial Results and Continued Portfolio Progress - GlobeNewswire

Metsera Reports Fourth Quarter and Full Year 2024 Financial Results and Continued Portfolio Progress  GlobeNewswire

Metsera Reports Fourth Quarter and Full Year 2024 Financial Results and Continued Portfolio Progress - GlobeNewswire

Click here to get full coverage on Metsera to Present at Goldman Sachs 46th Annual Global Healthcare Conference - GlobeNewswire

Metsera to Present at Goldman Sachs 46th Annual Global Healthcare Conference  GlobeNewswire

Metsera to Present at Goldman Sachs 46th Annual Global Healthcare Conference - GlobeNewswire

Click here to get full coverage on Metsera Rings the Nasdaq Stock Market Opening Bell - Nasdaq

Metsera Rings the Nasdaq Stock Market Opening Bell  Nasdaq

Metsera Rings the Nasdaq Stock Market Opening Bell - Nasdaq

Click here to get full coverage on This weight-loss drug stock could deliver a 90% return in 2025 - TradingView

This weight-loss drug stock could deliver a 90% return in 2025  TradingView

This weight-loss drug stock could deliver a 90% return in 2025 - TradingView

Click here to get full coverage on Obesity-focused Metsera files IPO just 9 months after emerging - Fierce Biotech

Obesity-focused Metsera files IPO just 9 months after emerging  Fierce Biotech

Obesity-focused Metsera files IPO just 9 months after emerging - Fierce Biotech

Click here to get full coverage on Metsera Stock Climbs On Positive Results From Early Stage Trial For Investigational Weight-Loss Drug: Retail Chatter Explodes - Stocktwits

Metsera Stock Climbs On Positive Results From Early Stage Trial For Investigational Weight-Loss Drug: Retail Chatter Explodes  Stocktwits

Metsera Stock Climbs On Positive Results From Early Stage Trial For Investigational Weight-Loss Drug: Retail Chatter Explodes - Stocktwits

Click here to get full coverage on Metsera reports promising Phase 1 trial results for obesity treatment - Investing.com

Metsera reports promising Phase 1 trial results for obesity treatment  Investing.com

Metsera reports promising Phase 1 trial results for obesity treatment - Investing.com

Click here to get full coverage on OH steam reforming (MTSR) to manufacture H - ScienceDirect.com

OH steam reforming (MTSR) to manufacture H  ScienceDirect.com

OH steam reforming (MTSR) to manufacture H - ScienceDirect.com

Click here to get full coverage on Cantor Fitzgerald maintains overweight on Metsera shares - Investing.com

Cantor Fitzgerald maintains overweight on Metsera shares  Investing.com

Cantor Fitzgerald maintains overweight on Metsera shares - Investing.com

Click here to get full coverage on Cantor Fitzgerald initiates Metsera with overweight rating - Investing.com

Cantor Fitzgerald initiates Metsera with overweight rating  Investing.com

Cantor Fitzgerald initiates Metsera with overweight rating - Investing.com

Click here to get full coverage on Metsera plunges 44% after InvestingPro’s overvaluation warning By Investing.com - Investing.com

Metsera plunges 44% after InvestingPro’s overvaluation warning By Investing.com  Investing.com

Metsera plunges 44% after InvestingPro’s overvaluation warning By Investing.com - Investing.com

Click here to get full coverage on Metsera Prices Initial Public Offering at $18 Per Share - The Healthcare Technology Report.

Metsera Prices Initial Public Offering at $18 Per Share  The Healthcare Technology Report.

Metsera Prices Initial Public Offering at $18 Per Share - The Healthcare Technology Report.

Click here to get full coverage on Busy day for biotech IPOs as Metsera, Maze go public with offerings totaling nearly $400M - Fierce Biotech

Busy day for biotech IPOs as Metsera, Maze go public with offerings totaling nearly $400M  Fierce Biotech

Busy day for biotech IPOs as Metsera, Maze go public with offerings totaling nearly $400M - Fierce Biotech

Click here to get full coverage on Metsera initiated with an Overweight at Wells Fargo - TipRanks

Metsera initiated with an Overweight at Wells Fargo  TipRanks

Metsera initiated with an Overweight at Wells Fargo - TipRanks

Click here to get full coverage on Guggenheim sets Metsera stock Buy rating, $56 target - Investing.com

Guggenheim sets Metsera stock Buy rating, $56 target  Investing.com

Guggenheim sets Metsera stock Buy rating, $56 target - Investing.com

Click here to get full coverage on metsera reports positive phase 1 trial results for obesity drug By Investing.com - Investing.com UK

metsera reports positive phase 1 trial results for obesity drug By Investing.com  Investing.com UK

metsera reports positive phase 1 trial results for obesity drug By Investing.com - Investing.com UK

Click here to get full coverage on Metsera's Q4 Net Loss Widens, Operating Expenses Rise; Shares Higher - MarketScreener

Metsera's Q4 Net Loss Widens, Operating Expenses Rise; Shares Higher  MarketScreener

Metsera's Q4 Net Loss Widens, Operating Expenses Rise; Shares Higher - MarketScreener

Click here to get full coverage on MicroStrategy (MSTR) Opens With 13% Surge - U.Today

MicroStrategy (MSTR) Opens With 13% Surge  U.Today

MicroStrategy (MSTR) Opens With 13% Surge - U.Today

Click here to get full coverage on Metsera Prices of Initial Public Offering - citybiz

Metsera Prices of Initial Public Offering  citybiz

Metsera Prices of Initial Public Offering - citybiz

Click here to get full coverage on Metsera’s IPO Raises $275M to Show How Its Obesity Drugs Can Top Current GLP-1s - MedCity News

Metsera’s IPO Raises $275M to Show How Its Obesity Drugs Can Top Current GLP-1s  MedCity News

Metsera’s IPO Raises $275M to Show How Its Obesity Drugs Can Top Current GLP-1s - MedCity News

Click here to get full coverage on Google Ventures-Backed Biotech Metsera Seeks $292 Million in IPO - BNN Bloomberg

Google Ventures-Backed Biotech Metsera Seeks $292 Million in IPO  BNN Bloomberg

Google Ventures-Backed Biotech Metsera Seeks $292 Million in IPO - BNN Bloomberg

Click here to get full coverage on Science Applications Posts Better-Than-Expected Earnings, Joins Qifu Technology, Baidu, American Eagle And Other Big Stocks Moving Higher On Monday - Alpha Technology Group (NASDAQ:ATGL), American Eagle Outfitters (NYSE:AEO) - Benzinga

Science Applications Posts Better-Than-Expected Earnings, Joins Qifu Technology, Baidu, American Eagle And Other Big Stocks Moving Higher On Monday - Alpha Technology Group (NASDAQ:ATGL), American Eagle Outfitters (NYSE:AEO)  Benzinga

Science Applications Posts Better-Than-Expected Earnings, Joins Qifu Technology, Baidu, American Eagle And Other Big Stocks Moving Higher On Monday - Alpha Technology Group (NASDAQ:ATGL), American Eagle Outfitters (NYSE:AEO) - Benzinga

Click here to get full coverage on News - New robots help EOD teams do jobs safer, better, faster - DVIDS

News - New robots help EOD teams do jobs safer, better, faster  DVIDS

News - New robots help EOD teams do jobs safer, better, faster - DVIDS

Click here to get full coverage on M'sian livestock industry's total trade up 23.2% to RM1.4b in 2023 — official data - The Edge Malaysia

M'sian livestock industry's total trade up 23.2% to RM1.4b in 2023 — official data  The Edge Malaysia

M'sian livestock industry's total trade up 23.2% to RM1.4b in 2023 — official data - The Edge Malaysia

Click here to get full coverage on FIG 2 Differential regulation of MtsR-regulated operons in GAS and GBS... - researchgate.net

FIG 2 Differential regulation of MtsR-regulated operons in GAS and GBS...  researchgate.net

FIG 2 Differential regulation of MtsR-regulated operons in GAS and GBS... - researchgate.net

Click here to get full coverage on Figure 3. Synthesis reaction of melamine and formaldehyde resulting in... - researchgate.net

Figure 3. Synthesis reaction of melamine and formaldehyde resulting in...  researchgate.net

Metsera, Inc. Common Stock (MTSR)

Price Chart

Key Statistics

Technicals

About MTSR

Latest News

Wall Street Analysts See an 89.66% Upside in Metsera Inc. (MTSR): Can the Stock Really Move This High? - Yahoo Finance

Promising Results Of Amylin Analogs In Obesity: Metsera Case Review (NASDAQ:MTSR) - Seeking Alpha

MTSR Stock Price and Chart — NASDAQ:MTSR - TradingView

Advanced Charts

Top Gainers

Top Losers